NASDAQ : PMCB
PharmaCyte Biotech, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.3321 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.57M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 5.11M | 4.91M | 3.94M | 6.11M | 5.99M | 3.70M |
| Research & Development | 356.14K | 391.30K | 438.42K | 407.43K | 468.54K | 690.94K |
| Operating Expenses | 5.46M | 5.30M | 4.38M | 6.52M | 6.46M | 4.39M |
| Operating Income | -5.46M | -5.30M | -4.38M | -6.52M | -6.46M | -4.39M |
| Interest Expense | -509.00 | |||||
| Interest & Investment Income | 1.30M | 1.11M | 1.42M | 3.40M | 1.94M | 157.65K |
| Other Non Operating Income (Expenses) | -1.73M | -7.74M | 9.11M | 5.45M | 202.00K | -4.28K |
| EBT Excluding Unusual Items | -5.89M | -11.93M | 6.15M | 2.33M | -4.32M | -4.24M |
| Gain (Loss) on Sale of Investments | -8.82M | -6.06M | 26.53M | |||
| Asset Writedown | -1.55M | -1.55M | -2.00M | |||
| Legal Settlements | 106.00K | 106.00K | -2.02M | |||
| Pretax Income | -16.15M | -19.42M | 30.66M | 333.76K | -4.32M | -4.24M |
| Net Income | -16.15M | -19.42M | 30.66M | 333.76K | -4.32M | -4.24M |
| Preferred Dividends & Other Adjustments | 4.49M | 3.78M | 7.29M | 17.57M | ||
| Net Income to Common | -20.63M | -23.21M | 23.36M | -17.24M | -4.32M | -4.24M |
| Shares Outstanding (Basic) | 9.36M | 8.38M | 7.33M | 9.58M | 19.49M | 15.52M |
| Shares Outstanding (Diluted) | 9.36M | 8.38M | 7.33M | 9.58M | 19.49M | 15.52M |
| EPS (Basic) | -2.20 | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 |
| EPS (Diluted) | -2.20 | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 |
| EBIT | -5.46M | -5.30M | -4.38M | -6.52M | -6.46M | -4.39M |
Balance sheet
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 17.74M | 18.60M | 15.17M | 50.18M | 68.04M | 85.40M |
| Short-Term Investments | 12.77M | 18.48M | 366.32K | |||
| Cash & Short-Term Investments | 30.51M | 37.08M | 15.54M | 50.18M | 68.04M | 85.40M |
| Other Receivables | 429.15K | 240.77K | ||||
| Receivables | 429.15K | 240.77K | 3.70M | |||
| Prepaid Expenses | 32.00K | 96.88K | 223.76K | 259.80K | 107.68K | 94.17K |
| Other Current Assets | 2.92M | |||||
| Total Current Assets | 30.97M | 37.42M | 22.38M | 50.44M | 68.15M | 85.49M |
| Long-Term Investments | 22.47M | 1.57M | 1.57M | |||
| Other Intangible Assets | 1.55M | 1.55M | 3.55M | 3.55M | ||
| Other Long-Term Assets | 5.74M | 9.33M | 8.77M | 7.91M | 7.69K | 7.69K |
| Total Assets | 36.71M | 46.75M | 55.17M | 59.90M | 73.28M | 90.62M |
| Accounts Payable | 390.54K | 271.10K | 399.20K | 389.37K | 128.28K | 205.36K |
| Accrued Expenses | 345.66K | 497.83K | 521.08K | 735.20K | 458.30K | 499.01K |
| Other Current Liabilities | 32.49K | 57.49K | 1.99M | 6.30M | ||
| Total Current Liabilities | 768.68K | 826.42K | 2.91M | 7.42M | 586.58K | 704.37K |
| Other Long-Term Liabilities | 6.13M | 10.95M | 363.00K | 12.97M | ||
| Total Liabilities | 6.90M | 11.77M | 3.28M | 20.39M | 586.58K | 704.37K |
| Common Stock | 2.60K | 2.60K | 2.17K | 2.17K | 2.16K | 2.07K |
| Additional Paid-In Capital | 182.01M | 182.72M | 181.49M | 185.33M | 202.23M | 201.58M |
| Retained Earnings | -109.47M | -104.39M | -84.97M | -115.63M | -115.96M | -111.65M |
| Treasury Stock | -45.01M | -45.01M | -44.61M | -42.04M | -13.56M | |
| Comprehensive Income & Other | 395.59K | 396.20K | -23.87K | -23.51K | -23.00K | -15.76K |
| Total Common Equity | 27.93M | 33.71M | 51.89M | 27.65M | 72.69M | 89.92M |
| Shareholders' Equity | 29.82M | 34.98M | 51.89M | 39.51M | 72.69M | 89.92M |
| Total Liabilities & Equity | 36.71M | 46.75M | 55.17M | 59.90M | 73.28M | 90.62M |
| Net Cash (Debt) | 30.51M | 37.08M | 15.54M | 50.18M | 68.04M | 85.40M |
| Net Cash Per Share | 3.26 | 4.43 | 2.12 | 5.24 | 3.49 | 5.50 |
| Filing Date Shares Outstanding | 10.74M | 10.74M | 6.80M | 7.71M | 8.78M | 20.75M |
| Total Common Shares Outstanding | 10.74M | 10.74M | 6.80M | 8.04M | 16.79M | 20.72M |
| Working Capital | 30.21M | 36.59M | 19.46M | 43.02M | 67.56M | 84.79M |
| Book Value Per Share | 2.60 | 3.14 | 7.64 | 3.44 | 4.33 | 4.34 |
| Tangible Book Value | 27.93M | 33.71M | 50.34M | 26.10M | 69.14M | 86.37M |
| Tangible Book Value Per Share | 2.60 | 3.14 | 7.41 | 3.25 | 4.12 | 4.17 |
Cash flow statement
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -16.15M | -19.42M | 30.66M | 333.76K | -4.32M | -4.24M |
| Asset Writedown & Restructuring Costs | 1.55M | 1.55M | 2.00M | |||
| Loss (Gain) From Sale of Investments | 8.82M | 6.06M | -26.53M | 1.57M | ||
| Stock-Based Compensation | 1.07M | 1.13M | 478.64K | 674.69K | 647.68K | 112.80K |
| Other Operating Activities | 1.93M | 7.47M | -8.94M | -7.03M | 171.74K | |
| Change in Accounts Payable | -74.67K | -128.10K | 9.84K | 261.09K | -242.95K | 33.10K |
| Change in Other Net Operating Assets | -1.08M | -1.80M | 1.35M | 37.80K | -54.22K | -24.06K |
| Operating Cash Flow | -3.94M | -5.15M | -2.98M | -2.15M | -3.79M | -4.12M |
| Investment in Securities | -3.00M | -3.00M | -7.00M | |||
| Other Investing Activities | 5.00M | 5.00M | -5.00M | |||
| Investing Cash Flow | 2.00M | 2.00M | -7.00M | -5.00M | ||
| Long-Term Debt Repaid | -50.80K | |||||
| Net Debt Issued (Repaid) | -50.80K | |||||
| Issuance of Common Stock | 1.05M | 1.05M | 70.00 | 880.00 | 87.36M | |
| Repurchase of Common Stock | -401.62K | -401.62K | -2.54M | -28.20M | -13.56M | |
| Preferred Dividends Paid | -329.40K | -246.00K | ||||
| Dividends Paid | -329.40K | -246.00K | ||||
| Financing Cash Flow | 6.50M | 6.58M | -25.03M | -10.71M | -13.56M | 87.31M |
| Foreign Exchange Rate Adjustments | 2.33K | 3.07K | -358.00 | -508.00 | -7.25K | 4.62K |
| Net Cash Flow | 4.56M | 3.43M | -35.01M | -17.86M | -17.36M | 83.20M |
| Levered Free Cash Flow | 2.57M | 2.22M | -13.34M | 3.28M | -3.52M | -2.62M |
| Unlevered Free Cash Flow | 2.57M | 2.22M | -13.34M | 3.28M | -3.52M | -2.62M |
| Cash Interest Paid | 509.00 | |||||
| Cash Income Tax Paid | 1.60K | 1.60K | ||||
| Change in Working Capital | -1.15M | -1.93M | 1.36M | 298.89K | -297.17K | 9.04K |
Ratios
Fiscal year May - April; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 3.44M | 7.75M | 8.51M | 17.92M | 50.93M | 48.28M |
| Enterprise Value | -27.08M | -11.91M | -8.25M | -20.48M | -21.71M | -38.36M |
| Last Close Price | 0.30 | 0.72 | 1.24 | 2.12 | 2.92 | 2.33 |
| PE Ratio | 0.36 | |||||
| PB Ratio | 0.12 | 0.22 | 0.16 | 0.45 | 0.70 | 0.54 |
| P/TBV Ratio | 0.12 | 0.23 | 0.17 | 0.69 | 0.74 | 0.56 |
| Net Debt / Equity Ratio | -1.02 | -1.06 | -0.30 | -1.27 | -0.94 | -0.95 |
| Quick Ratio | 40.25 | 45.16 | 5.33 | 6.76 | 115.99 | 121.24 |
| Current Ratio | 40.30 | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 |
| Return on Equity (ROE) | -43.99% | -44.72% | 67.08% | 0.60% | -5.31% | -8.78% |
| Return on Assets (ROA) | -8.34% | -6.50% | -4.75% | -6.12% | -4.92% | -5.60% |
| Return on Capital Employed (ROCE) | -15.20% | -11.50% | -8.40% | -12.40% | -8.90% | -4.90% |
| Earnings Yield | -688.60% | -250.60% | 360.19% | 1.86% | -8.47% | -8.78% |
| Buyback Yield / Dilution | -32.59% | -14.31% | 23.50% | 50.84% | -25.56% | -971.73% |